Nov. 4, 2013 - A new way of using blood pressure-lowering medications could prevent more than a fourth of heart attacks and strokes – up to 180,000 a year – while using less medication overall, according to new research from the University of Michigan Health System and the VA Ann Arbor Healthcare System.
Individualizing treatment recommendations using patients’ risk of heart disease after considering multiple factors – such as age, gender and whether or not the patient smokes – is a more effective way to treat patients than current methods, according to the study that appears in the medical journal, Circulation.
Related Archive Stories
“Preventive care should not be set aside simply because you’re getting older;” statement focuses on patients age 75 and older
Oct. 31, 2013
Current medical guidelines use a one-size-fits-all treatment approach based on target blood pressure values that leads to some patients being on too many medications and others being on too little, authors say.
Blood pressure medication is ultimately used to prevent associated heart disease and stroke. Researchers found that a person’s blood pressure level is often not the most important factor in determining if a blood pressure medication will prevent these diseases – but common practice is to base treatment strictly on blood pressure levels.
“Drugs that lower blood pressure are among the most effective and commonly used medications in the country, but we believe they can be used dramatically more effectively,” says lead author Jeremy Sussman, M.D., M.Sc., assistant professor of internal medicine in the Division of General Medicine at the U-M Medical School and research scientist at the Center for Clinical Management Research at the VA Ann Arbor Healthcare System.
“The purpose of these medications is not actually to avoid high blood pressure itself but to stop heart attacks, strokes and other cardiovascular diseases. We should guide use of medications by a patient’s risk of these diseases and how much adding a new medication decreases that risk – not solely on their blood pressure level. We found that people who have mildly high blood pressure but high cardiovascular risk receive a lot of benefit from treatment, but those with low overall cardiovascular risk do not.”
Current treatment guidelines emphasize specific blood pressure goals, with the majority of treatment driven specifically towards pushing blood pressure below 140/80 mmHg. However, authors say tailored blood pressure treatment decisions based on a patient’s overall cardiovascular disease risk – and the estimated benefits of advancing treatment – is a substantially more effective model of care.
Authors say new
blood pressure guidelines could help
patients make informed decisions about
their care. For example, if patients
knew that medication only slightly
reduced their risk of a heart attack or
stroke (e.g. from 8 in 100 to 6 in 100
over the next 10 years), they may decide
medication is not the right choice for
“In addition to resulting in more positive health outcomes for patients, this approach provides the type of information we need to guide individual decisions tailored to the patients’ preferences and priorities,” says senior author Rod Hayward, professor of Medicine and Public Health and senior investigator at the VA Center for Clinical Management Research.
“Our research shows how we can estimate how much taking more blood pressure medicine will reduce an individual’s risk of heart disease and strokes, so that they and their doctor can make the best decision for them.”
Both Sussman and Hayward are members of the U-M Institute for Healthcare Policy and Innovation and the Center for Clinical Management Research at Ann Arbor VA..
Additional Authors: Sandeep Vijan, M.D., M.S., associate professor of internal medicine at the U-M Medical School, research scientist at the VA Ann Arbor Health Care System and member of the IHPI.
Funding: U.S. Department of Veterans Affairs Quality Enhancement Research Initiative and the Methods Core of the Michigan Center for Diabetes and Translational Research of the National Institutes of Health (P60DK-20572)